文献速递泌尿生殖MR

接受主动监测的前列腺癌患者肿瘤体积监测:MRI表观扩散系数能否指示肿瘤生长

Monitoring Tumor Volume in Patients With Prostate Cancer Undergoing Active Surveillance: Is MRI Apparent Diffusion Coefficient Indicative of Tumor Growth?
PubMed 文献 · AJR Am J Roentgenol · 2017-06-13

研究纳入151例接受主动监测的前列腺癌男性,在间隔中位1.9年的两次直肠内MRI上测量优势前列腺内病灶体积与ADC。34.4%的肿瘤出现可测量性体积增长;基线ADC在有无可测量生长者间无显著差异(P=0.06),但ADC变化百分比在两组间有显著差异。ADC下降5.8%提示肿瘤体积可测量性增长,敏感度54.9%、特异度77.0%、AUC 0.67。

要点

  • ADC变化百分比与肿瘤体积变化百分比呈负相关(r=-0.31,P=0.0001)。
  • 基线ADC与基线肿瘤体积呈负相关(r=-0.42,P=0.001)。
  • ADC下降5.8%判断体积可测量增长:敏感度54.9%、特异度77.0%、AUC 0.67。

核心结论

  • 约2年主动监测后34.4%的男性肿瘤体积出现可测量性增长,ADC变化可能用于识别有可测量生长的肿瘤。

研究设计与样本

  • 研究纳入151例接受主动监测的男性(平均年龄68.1±7.4岁,范围50-83岁),在间隔中位1.9年的两次直肠内MRI上记录三维全前列腺、分区及肿瘤体积测量结果;肿瘤位置经直肠超声或模板活检确认,在最大病灶层面测量ADC;20例随机选取患者由同一观察者间隔大于4个月重复测量并计算测量一致性界限。

诊断标准与关键数值

  • 以超过测量一致性上限的肿瘤体积增加定义为可测量生长;ADC下降5.8%指示肿瘤体积可测量性增长,敏感度54.9%、特异度77.0%、AUC 0.67。

临床应用与阅片要点

  • 可测量生长组ADC变化百分比为-6.8%±12.3%,无可测量生长组为0.23%±10.1%(P=0.0005)。
  • 基线ADC在有无可测量生长组间无显著差异(P=0.06)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study was to measure longitudinal change in tumor volume of the dominant intraprostatic lesion and determine whether baseline apparent diffusion coefficient (ADC) and change in ADC are indicative of tumor growth in patients with prostate cancer undergoing active surveillance.

SUBJECTS AND METHODS: The study group included 151 men (mean age, 68.1 ± 7.4 [SD] years; range, 50-83 years) undergoing active surveillance with 3D whole prostate, zonal, and tumor volumetric findings documented at endorectal MRI examinations performed at two time points (median interval, 1.9 years). Tumor (location confirmed at transrectal ultrasound or template biopsy) ADC was measured on the slice with the largest lesion. Twenty randomly selected patients had the measurements repeated by the same observer after a greater than 4-month interval, and the limits of agreement of measurements were calculated. Tumor volume increases greater than the upper limit of agreement were designated measurable growth, and their baseline ADCs and change in ADC were compared with those of tumors without measurable growth (independent-samples t test).

RESULTS: Fifty-two (34.4%) tumors increased measurably in volume. Baseline ADC and tumor volume were negatively correlated (r = -0.42, p = 0.001). Baseline ADC values did not differ between those with and those without measurable growth (p = 0.06), but change in ADC was significantly different (-6.8% ± 12.3% for those with measurable growth vs 0.23% ± 10.1% for those without, p = 0.0005). Percentage change in tumor volume and percentage change in ADC were negatively correlated (r = -0.31, p = 0.0001). A 5.8% reduction in ADC indicated a measurable increase in tumor volume with 54.9% sensitivity and 77.0% specificity (AUC, 0.67).

CONCLUSION: Tumor volume increased measurably in 34.4% of men after 2 years of active surveillance. Change in ADC may be used to identify tumors with measurable growth.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Morgan VA, Parker C, MacDonald A, et al. Monitoring Tumor Volume in Patients With Prostate Cancer Undergoing Active Surveillance: Is MRI Apparent Diffusion Coefficient Indicative of Tumor Growth? AJR Am J Roentgenol. 2017. PMID: 28609110. doi:10.2214/AJR.17.17790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。